一种新的抗体疗法消除了所有18名受试病人中可检测到的多重骨髓瘤,显示出进行功能治疗的可能性。 A new antibody therapy eliminated detectable multiple myeloma in all 18 trial patients, showing potential for a functional cure.

新的抗体疗法“linvoseltamab”在早期试验18名病人时,在治疗血癌——血癌——的多种骨髓瘤方面,显示出令人乐观的成果。 A new antibody therapy, linvoseltamab, showed promising results in treating multiple myeloma, a blood cancer, in an early trial of 18 patients. 在经过长达六个治疗周期之后,根据高度敏感的测试,在任何参与者中都没有发现可检测的癌症。 After up to six treatment cycles, no detectable cancer was found in any participant, according to highly sensitive tests. 这种双特异性抗体通过向CD3和BCMA,将T细胞与髓瘤细胞结合起来,从而促进免疫系统对疾病的攻击. The bispecific antibody links T cells to myeloma cells by targeting CD3 and BCMA, boosting the immune system’s attack on the disease. 研究者将结果称为“极其令人印象深刻”,认为治疗可能消除骨髓移植的需要,提供长期控制,可能是一种功能性治疗。 Researchers called the outcomes “extremely impressive,” suggesting the treatment may eliminate the need for bone marrow transplants and offer long-term control, possibly a functional cure. 肺炎和呼吸道感染等副作用是可以管理的。 Side effects like neutropenia and respiratory infections were manageable. 调查结果在美国血病学学会会议上作了介绍,但需要进行更大的试验,以证实结果。 The findings were presented at the American Society of Hematology meeting, but larger trials are needed to confirm results.